Hanmi Pharm. Co., Ltd. (KRX:128940)

Market Cap	5.17T +43.8%
Revenue (ttm)	1.55T +4.5%
Net Income	172.44B +58.3%
EPS	13,587.94 +58.2%
Shares Out	12.69M
PE Ratio	29.99
Forward PE	24.55
Dividend	2,000.00 (0.51%)
Ex-Dividend Date	Mar 30, 2026

Volume	37,369
Open	390,500
Previous Close	392,500
Day's Range	389,500 - 409,500
52-Week Range	275,500 - 647,000
Beta	0.49
Analysts	Buy
Price Target	599,166.67 (+47.04%)
Earnings Date	Jul 28, 2026

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,400
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2025, Hanmi Pharm.'s revenue was 1.55 trillion, an increase of 3.48% compared to the previous year's 1.50 trillion. Earnings were 169.55 billion, an increase of 39.76%.

Analyst Summary

According to 12 analysts, the average rating for 128940 stock is "Buy." The 12-month stock price target is ₩599,167, which is an increase of 47.04% from the latest price.

Price Target

₩599,167

(47.04% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 11, 2026

Data Sources Report a data error